Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
暂无分享,去创建一个
R A Rifkind | C. Cordon-Cardo | H. Scher | H. Thaler | P. Marks | D. Agus | L. Butler | B. Higgins | A. Rose | V. Richon | R. Rifkind | V M Richon | P A Marks | C Cordon-Cardo | H I Scher | H T Thaler | L M Butler | D B Agus | B Higgins | A Rose | PA Marks | Adam Rose
[1] M. Resnick,et al. Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.
[2] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[3] S. Schwartz,et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. , 1996, Cancer research.
[4] N. Weigel,et al. 1 , 25-Dihydroxyvitamin D 3 and 9-cis-Retinoic Acid Act Synergistically to Inhibit the Growth of LNCaP Prostate Cells and Cause Accumulation of Cells in G 1 * , 1997 .
[5] C. Cordon-Cardo,et al. Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. , 1999, Journal of the National Cancer Institute.
[6] R. Vessella,et al. Inhibition of tumorigenic potential and prostate‐specific antigen expression in LNCaP human prostate cancer cell line by 13‐cis‐retinoic acid , 1994, International journal of cancer.
[7] P. Marks,et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors , 1999, Nature.
[8] P. Marks,et al. Induced differentiation, the cell cycle, and the treatment of cancer. , 1996, Pharmacology and Therapeutics.
[9] P. Marks,et al. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. , 1999, Cancer research.
[10] D. Fairlie,et al. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate , 1999, British Journal of Cancer.
[11] S. Schwartz,et al. CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma. , 1994, Cancer research.
[12] S. Shack,et al. Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. , 1993, The Journal of clinical investigation.
[13] M. Mason,et al. Cancer of the prostate , 2003 .
[14] N. Weigel,et al. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. , 1997, Endocrinology.
[15] A. Wolffe,et al. The nucleosome: a powerful regulator of transcription. , 1998, Progress in nucleic acid research and molecular biology.
[16] R. Santucci,et al. Effects of phenylbutyrate on proliferation and apoptosis in human prostate cancer cells in vitro and in vivo. , 1999, International journal of oncology.
[17] G. Miller,et al. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] Hickman Ja,et al. Differentiation: a suitable strategy for cancer chemotherapy? , 1993, Anti-cancer drug design.
[19] K. Struhl. Histone acetylation and transcriptional regulatory mechanisms. , 1998, Genes & development.
[20] P. Marks,et al. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). , 1999, Anticancer research.
[21] J. Nelson,et al. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] J. Stowell,et al. The synthesis of N-hydroxy-N'-phenyloctanediamide and its inhibitory effect on proliferation of AXC rat prostate cancer cells. , 1995, Journal of medicinal chemistry.
[23] G. Miller,et al. Three synthetic vitamin D analogues induce prostate-specific acid phosphatase and prostate-specific antigen while inhibiting the growth of human prostate cancer cells in a vitamin D receptor-dependent fashion. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[24] P. Marks,et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[25] R A Rifkind,et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Swinnen,et al. Control of LNCaP proliferation and differentiation: Actions and interactions of androgens, Iα,25‐dihydroxycholecalciferol, all‐trans retinoic acid, 9‐cis retinoic acid, and phenylacetate , 1996, The Prostate.
[27] M. Gleave,et al. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen‐independent progression in the human prostate LNCaP tumor model , 1998, Journal of cellular biochemistry.
[28] A. deMoura,et al. [Cancer of the prostate]. , 1962, Jornal do medico.
[29] D. Fairlie,et al. Tumor selectivity and transcriptional activation by azelaic bishydroxamic acid in human melanocytic cells. , 1997, Biochemical pharmacology.
[30] T. Stamey,et al. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. , 1994, Cancer research.
[31] C. Chen,et al. Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation. , 1998, Cancer research.